The activation of hepatic stellate cells (HSCs) is the key event of the pathogenesis of hepatic fibrosis. Platelet-derived growth factor (PDGF) is the most potent mitogen for HSCs, and PDGF receptor-b subunit (PDGFR-b) is required for the proliferation of HSCs induced by PDGF. In this study, a high gene-silencing-efficacy PDGFR-b small interference RNA (siRNA) was synthesized that could suppress the PDGFR-b expression and inhibit the activation and proliferation but could not induce the apoptosis of HSCs in vitro. To avoid the side effect of nonspecific interference of PDGFR-b, we constructed an HSCs-specific short hairpin RNA (shRNA) expression plasmid in which PDGFR-b shRNA was driven by a glial fibrillary acidic protein (GFAP) promoter. The doublestaining immunofluorescence examination indicated that GFAP promoter could target the transgene expression into HSCs in carbon tetrachloride induced acute injured rat's liver and bile duct ligation (BDL)-induced chronic injured rat's liver. Furthermore, HSCs-specific PDGFR-b shRNA could relieve liver injury and hepatic fibrosis in the rat's model induced by BDL. This study demonstrates that PDGFR-b siRNA may be presented as an antifibrogenic agent. The application of HSCs-specific RNA interference induced by the GFAP promoter might supply a new powerful tool for cellspecific gene therapy of hepatic fibrogenesis.
Introduction
Hepatic fibrosis characterized by the excess production and deposition of extracellular matrix components is a wound-healing process in a liver with chronic injury. Viral infection, alcoholic or any other factors that cause hepatocyte damage elicit an inflammatory reaction in the liver, and the production of the inflammatory reactions activates Kupffer cells, which release a number of soluble agents including cytokines, such as transforming growth factor-b 1 and platelet-derived growth factor (PDGF). The activation of hepatic stellate cells (HSCs) characterized by the morphological transition to myofibroblast-like cells is recognized as the key event of the pathogenesis of hepatic fibrosis. After activation, the HSCs migrate to the necroinflammatory areas and proliferate locally, resulting in the excess production of extracellular matrix and the formation of fibrous septa subsequently. Previous study showed that activated HSCs increased in hepatic fibrosis and decreased in the reversion of hepatic fibrosis. Therefore, inhibiting the activation, proliferation and migration of HSCs is one of the most important strategies to prevent hepatic fibrogenesis. 1 In fibrotic liver, PDGF is secreted from Kupffer cells, HSCs, bile duct epithelial cells and infiltrating leukocytes in fibrous septa and is recognized as the most potent mitogen for HSCs. 1 PDGF consists of four polypeptide chains, PDGF-A, -B, -C and -D. The former two isoforms are secreted as homo-or heterodimers and are involved in autocrine and paracrine stimulation of HSCs proliferation, 2 whereas the latter two form only homodimers with its function still uncertain. 3 All of the four isoforms bind to structurally related tyrosine kinase receptors that are homodimers or heterodimers of a or b subunits. PDGFRa is constitutively expressed in quiescent HSCs, whereas PDGFR-b is acquired as the activation of HSCs, the major cell type expressing PDGFR-b in the liver. PDGF-A binds only to a subunit, whereas PDGF-B is a ligand for both the receptor subunits. 3, 4 Of the different possible dimeric forms of PDGF, PDGF-BB is the strongest stimulator of HSC proliferation and intracellular signaling with concurrent predominant expression of PDGFR-b subunits in activated HSCs. Hepatic fibrosis induced by hepatic overexpression of PDGF-BB in transgenic mice was documented successfully, and the expression of PDGF and PDGFR-b in liver obtained from patients with chronic liver diseases also appears to be closely correlated to the extent of necroinflammation and fibrosis, demonstrating the importance of PDGF and PDGFR-b in hepatic fibrogenesis. 5, 6 For these reasons, targeting PDGF, PDGF receptor and molecules related to the PDGF intracellular signaling-transduction pathway is attractive for therapeutic intervention in hepatic fibrosis. Great advances have been made in gene therapy of hepatic fibrosis in recent years. 7 However, it remains a puzzle as to how to make the therapeutic genes express only in the liver and in the target cells such as HSCs. As we know, PDGF and its receptors play important roles in the recovery of damaged tissue pathologically. If we cannot restrict the expression of the therapeutic gene only in the liver and in HSCs, it may cause serious adverse effects on clinical application.
In this study, we inhibited the PDGFR-b expression by RNA interference to block the binding of PDGF and investigated its effect on the biological characteristics of HSCs in vitro. To avoid the nonspecific interference of PDGFR-b gene expression in other tissues and cells, we used cell-specific glial fibrillary acidic protein (GFAP) promoter to drive the expression of PDGFR-b shRNA (short hairpin RNA) in HSCs of liver and also investigated its antifibrogenic effect in vivo. To investigate the effect of PDGFR-b siRNA 957 on the activation and extracellular matrix production of HSCs, we detected mRNA expression of a-smooth muscle actin (a-SMA), connective tissue growth factor (CTGF), tissue inhibitor of metalloproteinase-1 (TIMP-1), collagen type I, transforming growth factor-b 1 and matrix metalloproteinase-2 by RT-PCR. The results demonstrated that a-SMA mRNA expression in HSCs was markedly elevated by PDGF-BB stimulation, which was blocked by PDGFR-b siRNA 957 . Furthermore, the upregulation of CTGF, TIMP-1 and collagen type I mRNA induced by PDGF-BB was eliminated by siRNA 957 . Additionally, siRNA 957 could diminish the elevated expression of PDGF-B mRNA induced by PDGF-BB (Figure 1d) . However, the expressions of transforming growth factor-b 1 and matrix metalloproteinase-2 mRNA in HSCs were not affected by PDGFR-b siRNA 957 and/or PDGF-BB (data not shown). Figure 2d ).
GFAP promoter targets LacZ express into HSCs in the liver of acute injury
To locate LacZ reporter gene expression driven by GFAP promoter in the liver, we injected pGfa-shRNA-LacZ or pCMV-shRNA-LacZ by the hydrodynamics-based transfection method into normal rats, acute liver injury rats induced by carbon tetrachloride (CCl 4 ), and chronic liver injury rats induced by bile duct ligation (BDL). Immunofluorescence analysis indicated that b-galactosidasepositive cells were all distributed in the pericentral and portal areas of the hepatic lobule in normal rats, acute liver injury rats and chronic liver injury rats for both pCMV-shRNA-LacZ and pGfa-shRNA-LacZ treatment.
As expected, b-galactosidase-positive cells were fewer in normal livers treated with pGfa-shRNA-LacZ than in acute injured livers or chronic injured livers treated with the same plasmid. Immunofluorescence analysis also revealed that b-galactosidase proteins were detected in both hepatocytes and HSCs, which were positive for a-SMA and/or GFAP staining in the liver treated with pCMV-shRNA-LacZ, whereas in the liver treated with pGfa-shRNA-LacZ, b-galactosidase proteins were located in the perisinusoidal space and were co-expressed with GFAP and/or a-SMA. The results revealed that the GFAP promoter targeted the reporter gene LacZ specifically expressing in HSCs and the CMV promoterdirected LacZ expressing not only in HSCs but also in hepatocytes ( Figure 3 ).
PDGFR-b shRNA inhibits PDGFR-b expression in BDL rats
To determine the dose schedule of PDGFR-b siRNA expression plasmids in gene therapy of experimental hepatic fibrosis, we detected the inhibitory effect of PDGFR-b shRNA on PDGFR-b protein expression at different time points after pGfa-shRNA-LacZ treatment and BDL operation. Western blot analysis showed that PDGFR-b protein levels elevated gradually after BDL, and the PDGFR-b protein levels in pGfa-shRNA-LacZtreated rats decreased significantly at days 2 and 4 when compared with those in the BDL control rats. Nevertheless, no significant inhibitory effect was observed since day 6, implying that the downregulation effect of pGfa-shRNA-LacZ on PDGFR-b protein expression could retain up to 6 days, and we decide to perform the plasmids treatment once every 5 days ( Figure 4 ).
PDGFR-b shRNA relieves liver injury in BDL rats
To further investigate the effect of PDGFR-b shRNA on liver injury, the BDL rat model was used. Serum levels of total bilirubin, indirect bilirubin, alanine aminotransferase and aspartate aminotransferase elevated significantly in BDL rats as compared with the sham-operated rats. However, pGfa-shRNA-LacZ treatment markedly reduced the serum levels of total bilirubin, alanine aminotransferase and aspartate aminotransferase as compared with pGfa-NC-LacZ treatment rats, illustrating that HSCs-specific PDGFR-b shRNA could relieve liver injury induced by BDL (Figures 5b and c).
PDGFR-b shRNA inhibits HSC activation and ameliorates hepatic fibrosis in BDL rats
What we were concerned about next was the effect of HSCs-specific PDGFR-b shRNA on hepatic fibrosis. Immunohistochemical examination revealed that PDGFR-b and a-SMA protein expressions increased significantly in the BDL rats, which were suppressed by pGfa-shRNA-LacZ treatment (Figures 6a and b ).
Masson's trichrome staining of liver sections in the BDL rats and the pGfa-NC-LacZ treatment rats showed periportal fibrosis with short septa extending into lobules or porto-portal septa, and severe cholestasis and bile duct hyperplasia were also observed, whereas hepatic fibrosis was significantly ameliorated in the pGfa-shRNA-LacZ treatment rats as compared with the pGfa-NC-LacZ treatment rats ( Figure 6a and Table 1 ). In addition, the hydroxyproline content increased more than twofold in BDL rats when compared with the shamoperated rats, whereas pGfa-shRNA-LacZ treatment decreased about half of the hydroxyproline content in BDL rats (Figure 6c ). These results clearly indicate that PDGFR-b shRNA could ameliorate hepatic fibrosis induced by BDL.
Discussion
The coupling of PDGF-BB to its tyrosine kinase receptor PDGFR-b induces autophosphorylation of tyrosine residues within the cytoplasmic domain, which results in the recruitment and activation of receptor-associated proteins, followed by the initiation of the mitogenactivated protein kinases signal pathway, 8 which is necessary for the proliferation of activated HSCs induced by PDGF. 9 As PDGF and PDGFR-b have been implicated in hepatic fibrosis, many antifibrogenic strategies focus on reducing the secretion of PDGF, thus inhibiting the coupling of PDGF and PDGFR. The antisense mRNA of RNase to promote hydrolysis of target RNA. 18 Recently, the applications of RNA interference in the gene therapy of liver disease have been presented successfully. 19 The siRNA against PDGFR-b presented in this study was also confirmed to knockdown PDGFR-b expression, diminish ERK phosphorylation and c-fos expression, the two important processes in the mitogen-activated protein kinase signal pathway, and result in antifibrogenic effect in vitro and in vivo.
Activated HSCs constitute one of the cell types secreting PDGF. It was reported that PDGF-B overexpression in transgenic mice could result in the upregulated PDGFR-b mRNA expression in liver 6 and that the soluble PDGFR-b was able to decrease the secretion of PDGF-BB in cultured HSCs, 16 confirming the positive feedback loop between PDGF-BB secretion and PDGFR-b expression in the activated HSCs. In this study, the decreased expression of PDGFR-b and PDGF-B mRNA were induced by PDGFR-b siRNA, implying that the autocrine loop of PDGF-BB in the activated HSCs could be interrupted by PDGFR-b siRNA. It was reported that PDGF play major roles in the maintainance of HSC activation 6 and that a-SMA expression could be downregulated by the inhibitors of PDGF, 20 which were confirmed by this study as demonstrated by significantly increased a-SMA mRNA levels by PDGF-BB stimulation and the markedly decreased a-SMA mRNA levels induced by PDGFR-b siRNA.
Hepatic fibrosis occurs when the rate of matrix synthesis exceeds that of matrix degradation, and matrix degradation occurs predominantly consequent on the action of matrix metalloproteinases, which are governed by tissue inhibitors of metalloproteinase (TIMPs). Matrix metalloproteinase/TIMP balance is thought to play a crucial role in the pathogenesis of hepatic fibrosis. 21 In this study, the upregulation of TIMP-1 mRNA expression was induced by PDGF-BB in HSCs, which fits in well with another study. 22 CTGF secreted by HSCs is overexpressed in hepatic fibrosis. Exogenous CTGF was able to promote HSCs adhesion, proliferation, migration and Targeted PDGFR-b siRNA ameliorate hepatic fibrosis S-W Chen et al collagen production, 23 and it was also documented as the activator of the mitogen-activated protein kinase signal pathway. 24 Our study also demonstrated that the increased expression of CTGF induced by PDGF-BB was accompanied by the elevated collagen I mRNA and the activation of the mitogen-activated protein kinase signal pathway in HSCs and that such an effect of PDGF-BB was blocked by PDGFR-b siRNA. The apoptosis of HSCs is one of the major mechanisms for the reversion of hepatic fibrosis. 25 However, the results in this study indicate that the collagen production was reduced with the decreased expression of PDGFR-b, whereas the amount of apoptotic HSCs was not markedly affected, 26, 27 although they also promote the formation of the fibrosis of the liver, pancreas, kidney, lung and myocardium. [28] [29] [30] [31] New vectors should be developed to induce cell-specific expression of siRNA.
A well-established method to target transgene expression in specific tissues or cells is the delivery of transgenes under the control of specific promoters or transcriptional regulatory units. Gene targeting to HSCs is potentially possible by expressing transgenes under the control of promoters upregulated in the course of transdifferentiation, or the transcriptional regulatory units exclusively expressed in HSCs. The promoters of several genes including CSRP2, SM22a and TIMP-1 have been developed to mediate HSCs-specific expression in vitro, but none is able to direct a specific or inducible expression of transgenes in HSCs in vivo. 32, 33 A previous study demonstrated that a tissue-specific enhancer of the mouse a2(I) collagen gene could drive downstream a gene expressing specifically in the activated HSCs in CCl 4 -induced fibrotic liver, and a cell-specific antifibrogenic gene therapy that was based on this system was reported successfully. 34 GFAP, an intermediate filament protein, was traditionally considered to be a biomarker of astrocytes of the central nervous system. 35 It was reported that the human GFAP promoter containing 2.2 kb could drive astrocytes-specific gene expression. 36 Since the 1980s, GFAP was also documented as a marker for HSCs, including activated and quiescent HSCs. 37, 38 Desmin, another intermediate filament protein, is generally acknowledged as a marker of HSCs and it is widely applied to identify HSCs. A previous study demonstrated that GFAP had almost the same expression profile as desmin in fibrotic rat liver induced by CCl 4 and BDL, but HSCs in fibrotic/cirrhotic human liver were immunoreactive to GFAP but not desmin, suggesting that GFAP was superior to desmin as a marker of HSCs. 38 The 2.2 kb GFAP promoter was also reported to direct transgene expression specifically in a rat HSC line. 39 On the other hand, a new shRNA expression vector, in which shRNA was embedded in a microRNA context driven by polymerase II promoters, such as cytomegalovirus (CMV), made the tissue or cell-specific expression of shRNAs possible. 40, 41 To achieve HSC-specific expression of PDGFR-b siRNA in vivo, we reconstructed the pCMR30 shRNA expression vector by replacement of the CMV promoter with the GFAP promoter. Our in vivo study clearly indicated that the GFAP promoter could target PDGFR-b shRNA into HSCs in acute injured liver induced by CCl 4 and chronic injured liver induced by BDL and that the HSC-specific PDGFR-b shRNA could ameliorate liver injury and hepatic fibrosis in rats.
In conclusion, we demonstrate for the first time that the GFAP promoter containing 2.2 kb is sufficient to drive gene expression specifically in HSCs in vivo. Moreover, the PDGFR-b shRNA expression system driven by the GFAP promoter exerts the ability to relieve experimental hepatic fibrosis, which may serve as a powerful tool for the cell-specific gene therapy of hepatic fibrogenesis.
Materials and methods

siRNA preparation
The targeted region of small interfering RNA (siRNA) was the coding sequence of PDGFR-b cDNA. The selected three pairs of 21-nucleotide RNAs and one pair of nonspecific nucleotide RNA followed by TT or TdG were chemically synthesized by Shanghai Sangon Biological Engineering and Technology and Service Co. Ltd (China) ( Table 2 ). The nonspecific nucleotide RNA served as a negative control of siRNA, and no homology was found between the nonspecific nucleotide RNA and PDGFR-b mRNA of rats by blast.
Generation of plasmids
Platelet-derived growth factor receptor-b shRNA and its negative control, corresponding to PDGFR-b siRNA 957 and nonspecific nucleotide RNA containing the 9-nt loop sequence (TTCAAGAGA) flanked by sense and antisense of siRNA sequences, were synthesized by PCR. To generate pCMV-shRNA-RFP in which PDGFR-b-shRNA was driven by CMV promoter and red fluorescent protein (RFP) was the reporter gene, PDGFR-b shRNA was inserted into the miR30-based shRNA expression system of pCMR30 Vector (Genechem, China). To construct pCMV-shRNA-LacZ, the fragment containing miR30-based PDGFR-b shRNA was PCR-cloned into the HindIII site of pMIR-REPORT b-gal Reporter Control Vector (Ambion, Austin, TX, USA), which supplied the LacZ reporter gene. The plasmid pGfa2-nlac2 containing the human GFAP promoter and mouse protamine 1 intron and polyadenylation signal on the 3 end was kindly provided by Dr M Brenner. 36 The GFAP promoter in pGfa2-clac was PCR-cloned into the EcoRI and BamHI site and replaced the CMV promoter of pCMV-shRNALacZ to generate pGfa-shRNA-LacZ. pGfa-NC-LacZ was generated by replacement of PDGFR-b shRNA in pGfa- Targeted PDGFR-b siRNA ameliorate hepatic fibrosis S-W Chen et al shRNA-LacZ with nonspecific nucleotide RNA as a negative control. All the constructed plasmids were verified by PCR and sequencing.
Cell culture and transfection
The rat HSC-T6 cell line was a generous gift from Dr Scott Friedman of the Mount Sinai School of Medicine in New York, 42 which was cultured in Dulbecco's modified medium containing 10% fetal bovine serum (Gibco, Grand Island, NY, USA) for screening the efficacy of PDGFR-b siRNA. Primary HSCs were isolated from SD rats (about 400 g body weight) by in situ perfusion, followed by centrifugation on a discontinuous gradient of metrizamide, as described previously. 43 The isolated HSCs were identified by their intrinsic vitamin A autofluorescence and by staining for desmin. Their purity was X95%. Cells were seeded in Dulbecco's modified medium containing 10% fetal bovine serum. Activated HSCs were obtained by subcultivation of HSCs at day 7 and then the cells were plated on new culture dishes. Transient transfection using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was carried out in 6-well plates with a 12.5 ml siRNA/35 mm culture plate when cells reach 60-80% confluence. The serum content was reduced to 0.25% fetal bovine serum 24 h later and the cells were stimulated with 20 ng ml À1 PDGF-BB (Sigma, St Louis, MO, USA) for another 48 h. To detect the phosphorylation of ERK protein, 50 mmol l À1 PD98059 (Sigma) or its vehicle dimethyl sulfoxide (Gibco) was added to the cells 30 min before PDGF-BB stimulation.
Proliferation assay
After PDGF-BB stimulation and/or siRNA transfected, cells were stimulated with 10 mM 5-bromodeoxyuridine (BrdU, Upstate, Billerica, MA, USA) for 1 h, followed by being fixed with 4% paraformaldehyde solution. Cells were then incubated with HCl followed by borate buffer at room temperature. BrdU in the nucleus was detected by immunocytochemical staining using a mouse monoclonal FITC-labeled anti-BrdU antibody (Abcam, Cambridge, UK). Light nuclear counterstaining was performed with 4,6-diamidino-2-phenylindole (Roche, Nutley, NJ, USA) for 15 min at room temperature before mounting. Cells were analyzed with a Leica TCS SP2 Confocal Microscope system (Leica, Solms, Germany). HSC proliferation was measured by green staining of nuclei that had incorporated BrdU. Results were expressed as mean±s.d. of cells that had incorporated BrdU (percentage of BrdU-positive cells).
Apoptosis assay
Apoptosis assay was performed according to the protocol of the Annexin V/PI Apoptosis Assay Kit (Jingmei, Shanghai, China). In brief, cells transfected with siRNA and/or stimulated by PDGF-BB mentioned above were harvested and washed in ice-cold phosphate-buffered saline. The cells were then resuspended in 250 ml binding buffer to a final concentration of 1 Â 10 6 cells per ml, and 100 ml of the cell suspension was aliquot into each test tube. Five ml of Annexin/FITC and 10 ml PI (20 mg ml Targeted PDGFR-b siRNA ameliorate hepatic fibrosis S-W Chen et al
RT-PCR assay
Total RNA of the cells transfected with siRNA and/or stimulated by PDGF-BB was isolated with Trizol reagent (Invitrogen). cDNA was amplified from RNA with the use of the RT-PCR kit (Takara, Otsu, Japan). Primers were designed according to Pubmed Genbank and synthesized by Shanghai Sangon Biological Engineering and Technology and Service Co. Ltd (China) ( Table 3) . Relative expression levels of mRNA were normalized against those of b-actin mRNA. Briefly, PCR was performed at 95 1C with initial denaturation for 5 min, followed by 30 cycles of amplification at 94 1C (1 min), 59 1C (1 min) and 72 1C (1 min). Finally, the samples were extended at 72 1C for 10 min. Aliquots of the synthesized PCR products were separated by electrophoresis on a 1.5% agarose gel and analyzed by Gel-Pro 3.1 software.
Western blot analysis
After siRNA transfection and/or PDGF-BB stimulation, whole cells were homogenized in lysis buffer. Phosphatase inhibitor (Sigma) was added to prevent protein dephosphorylation. PDGFR-b protein expression and ERK phosphorylation were detected by Western blot according to the protocol of the University of California (http://cancer.ucsd.edu/howelllab/Western.html). Primary antibodies used for western blot were directed against PDGFR-b (Santa Cruz, Santa Cruz, CA, USA), b-actin (Chemicon, USA), ERK and pERK (Santa Cruz). The reaction was visualized using horseradish peroxidase-conjugated anti-mouse-or anti-rabbit IgG (Chemicon, Billerica, MA, USA) as secondary antibodies.
Localization of LacZ gene expression in acute and chronic liver injury model in rats
All animals (male SD rats) weighing about 200 g were housed in cages with stainless steel wire tops and with 12-h light-dark cycles under standard animal laboratory conditions in the SPF-grade animal room of the experimental animal center of the second military medical university. The rats had free access to standard rat chow and water. This study was approved by the Local Ethical Committee of the second military medical university. To induce the acute liver injury model, 10 SD rats were peritoneal injected with 50% CCl 4 by 3 ml kg À1 body weight. Six hours later, plasmid pGfa-shRNA-LacZ or pCMV-shRNA-LacZ was injected through the tail vein (five rats in each group). The chronic liver injury model was induced by double ligation with 1/0 polipropilene sutures and transection of the common bile duct under aseptic conditions. Ten survival rats were divided into two groups 14 days after operation and received pGfashRNA-LacZ (n ¼ 5) or pCMV-shRNA-LacZ (n ¼ 5) treatment. As control, 10 normal rats were also divided into two groups: pGfa-shRNA-LacZ treatment group (n ¼ 5) and pCMV-shRNA-LacZ treatment group (n ¼ 5).
The hydrodynamics-based transfection method, defined as a rapid injection of a large volume of naked plasmid DNA solution into rats or mice through the tail veins, was an efficient method for expressing transgenes in animal organs especially the liver, 44, 45 and it was successfully applied to deliver siRNA to silence gene expression in vivo. 46 The plasmid solutions were also injected using this method. Briefly, 100 mg pGfa-shRNALacZ or pCMV-shRNA-LacZ was dissolved in 15 ml Ringer's solution, and a total amount of 15 ml solution/ 200 g body weight was injected in 17 s through the tail vein. All rats were anesthetized and perfused 24 h after plasmid injection, and livers were taken out and postfixed with 4% paraformaldehyde and 0.2% picric acid in phosphate buffer. Frozen liver sections (8 mm in thickness) were incubated with mouse anti-b-galactosidase monoclonal antibody (Promega, Madison, WI, USA), rabbit anti-GFAP polyclonal antibody (Boster, Wuhan, China) or rabbit anti-a-SMA polyclonal antibody (Bios, Beijing, China) for 20 h at 4 1C, then washed in phosphate-buffered saline and incubated for 30 min with Cy5-labeled anti-rabbit IgG antiserum and FITC-labeled anti-mouse IgG antiserum (Jackson, West Grove, PA, USA) at 1:100 dilution in phosphate-buffered saline. The sections were again washed in phosphate-buffered saline and then transferred to slides and coverslipped. GFAP and b-galactosidase immunofluorescence, or a-SMA and b-galactosidase immunofluorescence were visualized in the same sections with the Leica TCS SP2 Confocal Microscope system.
The expression of pGfa-shRNA-LacZ in BDL rats
To determine the dose schedule of plasmids treatment in gene therapy of experimental hepatic fibrosis, 50 male SD rats were divided into two groups: one group (25 rats) was treated with pGfa-shRNA-LacZ as described above and then received BDL operation; the other group (25 rats) received BDL operation only. The day of plasmid treatment and/or BDL was considered as 'day 0,' and every 3 rats were killed at different time points from then on. The right lobe of livers were taken and preserved at À70 1C for western blot, in which the antibodies against PDGFR-b and b-actin were used.
Animal model of hepatic fibrosis
Fifty-five male SD rats (190±15 g) were randomly assigned to the normal group (n ¼ 11), the sham-operated group (n ¼ 11) and the BDL group (n ¼ 33). In the BDL group, hepatic fibrosis was induced by common BDL as described above. In sham-operated rats, the operation was performed in the same way but without BDL and transection. The 33 BDL rats were treated as follows: model group (n ¼ 11, Ringer's solution); pGfa-shRNALacZ treatment group (n ¼ 11, 100 mg pGfa-shRNA-LacZ dissolved in Ringer's solution); and pGfa-NC-LacZ treatment group as a negative control (n ¼ 11, 100 mg pGfa-NC-LacZ dissolved in Ringer's solution). All the solutions were injected with hydrodynamics-based transfection method once every 5 days from the day before BDL operation. The animal treatment protocol was shown in Figure 5a . The injection volume and plasmids concentration at the first time were mentioned above. As the increased mortality of BDL rats by injection of the same volume solutions from the second time was observed in our preliminary experiment, we decreased the injection volume to 10 ml per 200 g body weight from the second time, whereas the amount of plasmids was still 100 mg every time. At the end of 2 weeks, the rats were killed and serum samples were collected for biochemical tests. The right lobe of livers were taken and some were soaked with 10% neutral formaldehyde for histology, whereas others were preserved at À70 1C for hydroxyproline content determination.
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Evaluation of hepatic fibrosis
To evaluate the pathogenesis of hepatic fibrosis semiquantitatively, Masson's trichrome staining was used. The stage of fibrosis was graded as follows: stage 0, normal connective tissue (no fibrosis); stage 1, fibrous portal expansion; stage 2, periportal fibrosis with short septa extending into lobules or rare porto-portal septa (intact architecture); stage 3, fibrous septa reaching adjacent portal tracts and terminal hepatic venule (architecture distortion, but no obvious cirrhosis); stage 4, diffuse nodular formation (cirrhosis). For quantitative assessment of hepatic fibrosis, total hepatic hydroxyproline content was determined in the alkaline hydrolysates of liver samples according to the protocol of Hydroxyproline Testing Kit (Jiancheng, Nanjing, China) and then measured with a spectrophotometer.
Immunohistochemistry for a-SMA and PDGFR-b on liver sections
The paraffin sections were deparaffinized using xylene and alcohol and hydrated to water, then treated with a-SMA polyclone antibody (Boster) and PDGFR-b antibody, followed by biotinylated second antibody and streptavidin peroxidase. The integrated optical intensity of a-SMA and PDGFR-b was semiquantified using Image-Pro Plus software.
Statistical analysis
Results were presented as means of three independent experiments (±s.d.). In the semiquantitive analysis of histological staging, nonparametric tests (Wilcoxon test) were used and other statistical analyses performed with an unpaired Student's t-test. Differences were considered as significant or highly significant at Po0.05 or Po0.01, respectively.
Abbreviations a-SMA, a-smooth muscle actin; BDL, bile duct ligation; CTGF, connective tissue growth factor; GFAP, glial fibrillary acidic protein; HSCs, hepatic stellate cells; PDGF, platelet-derived growth factor; PDGFR-b, PDGF receptor-b subunit; RT-PCR, reverse transcriptional-PCR; shRNA, short hairpin RNA; siRNA, small interfering RNA; TIMP-1, tissue inhibitor of metalloproteinase-1.
